Drugs / 608
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05604898 | Apr 2021 → May 2023 | psoriasis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 608 | “608 will be administered subcutaneously.” NCT05604898 ↗ |
| Action | Inhibit | “Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection” NCT05604898 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection” NCT05604898 ↗ |
| Route | Subcutaneous | “608 will be administered subcutaneously.” NCT05604898 ↗ |
| Target | IL17A | “Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection” NCT05604898 ↗ |